 SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 GLOBE NEWSWIRE -- Alector, Inc. Nasdaq: ALEC, a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020, at 11:00 a.m. ET. A live webcast of the fireside chat will be available on the Events Presentations page within the Investors section of the Alector website at A replay will be available on the Alector website for 30 days following the event.About Alector Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brains immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Companys product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimers disease. Alector is headquartered in South San Francisco, California. For additional information, please visit Media Erica Jefferson Vice President, Communications and Public Affairs Alector, Inc. 301-928-4650 Dan Budwick 973-271-6085 Alector, Inc. 